This activity is expired and is no longer available for CME credit.


Proliferative and Nonproliferative Diabetic Retinopathy: Weighing the Evidence for Medical Treatment

Author(s)/Faculty: Michael S. Ip, MD; Jorge A. Fortun, MD; Nadia K. Waheed, MD, MPH
Release Date: 4/27/2018Expiration Date: 4/17/2020
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
Although rapid advances have been made in the treatment of diabetic macular edema (DME), particularly with the use of intravitreal therapy, options for the management of diabetic retinopathy (DR) have remained limited. Until recently, the primary approach for the management of DR was the use of panretinal photocoagulation therapy. Additional treatment options for DR were discovered as a result of analysis of data from studies of anti-vascular endothelial growth factor (VEGF) therapy for DME. The RISE and RIDE pivotal trials demonstrated large, rapid, and sustained improvements in eyes with DME when treated with ranibizumab. Since then, new information on the optimal management of diabetic retinal disease with anti-VEGF therapy has been obtained from sub-analyses of these studies and their open-label extensions. Advances in knowledge of DR and its treatment have also been obtained from the Diabetic Retinopathy Clinical Research Network ( Protocol S trial, which is the first randomized, controlled trial to compare the anti-VEGF ranibizumab with laser therapy for the treatment of proliferative DR. This CME activity will review the current evidence regarding the efficacy of treatment for DR.